PT Medikaloka Hermina (HEAL) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
2 Dec, 2025Executive summary
Operates 51 hospitals across 36 cities in Indonesia, focusing on women and children care and a differentiated business model aligned with the JKN universal health coverage scheme.
Net revenues for the nine months ended September 30, 2025, reached Rp5,287,968 million, up from Rp5,026,528 million year-over-year.
Net income attributable to owners for the period was Rp356,017 million, a decrease from Rp468,160 million in the prior year.
Expanded network with four new hospitals established in 2024 and ongoing development in Bali and Central Java, targeting further growth by end of 2025.
Total assets increased to Rp11,805,141 million as of September 30, 2025, from Rp10,577,680 million at year-end 2024.
Financial highlights
Total revenue for 9M25 reached IDR 5,288 billion, up 5.2% year-over-year from 9M24.
PATMI for 9M25 was IDR 356 billion, down 24% year-over-year, reflecting margin pressure.
EBITDA for 9M25 was IDR 1,457 billion, nearly flat year-over-year, with EBITDA margin at 27.6%.
Gross profit for the period was Rp1,771,868 million, slightly down from Rp1,879,112 million year-over-year.
Operating income was Rp751,104 million, compared to Rp866,076 million in the same period last year.
Outlook and guidance
Two hospitals under development (Bali and Salatiga) are on track for opening in 4Q25, supporting continued expansion.
Management continues to focus on expanding hospital operations and capital investments, with significant construction in progress and advances for fixed asset purchases.
Latest events from PT Medikaloka Hermina
- Strong revenue and profit growth, robust expansion, and solid capital structure maintained.HEAL
Q2 202422 Aug 2025 - Revenue and net income surged in 9M24, supported by expansion and strong financials.HEAL
Q3 202422 Aug 2025 - Double-digit revenue and profit growth, strong margins, and continued network expansion.HEAL
Q4 202422 Aug 2025 - Revenue and profit declined, but equity, investments, and credit rating remain strong.HEAL
Q1 202522 Aug 2025 - Net income and margins fell despite higher revenue and asset growth in 6M25.HEAL
Q2 202522 Aug 2025